Brian J Christmas
Overview
Explore the profile of Brian J Christmas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
155
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kao C, Charmsaz S, Alden S, Brancati M, Li H, Balaji A, et al.
J Clin Invest
. 2024 Oct;
134(20).
PMID: 39403935
BACKGROUNDImmune-related adverse events (irAEs) and their associated morbidity/mortality are a key concern for patients receiving immune checkpoint inhibitors (ICIs). Prospective evaluation of the drivers of irAEs in a diverse pan-tumor...
2.
Fusco M, Casak S, Mushti S, Cheng J, Christmas B, Thompson M, et al.
Clin Cancer Res
. 2024 May;
30(15):3100-3104.
PMID: 38809262
On November 8, 2023, the FDA approved fruquintinib, an inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3, for the treatment of patients with metastatic colorectal cancer (mCRC)...
3.
Sidiropoulos D, Rafie C, Jang J, Castanon S, Baugh A, Gonzalez E, et al.
Cancer Immunol Res
. 2022 Feb;
10(5):656-669.
PMID: 35201318
Therapeutic combinations to alter immunosuppressive, solid tumor microenvironments (TME), such as in breast cancer, are essential to improve responses to immune checkpoint inhibitors (ICI). Entinostat, an oral histone deacetylase inhibitor,...
4.
Mirando A, Patil A, Rafie C, Christmas B, Pandey N, Stearns V, et al.
Oncoimmunology
. 2020 Sep;
9(1):1760685.
PMID: 32923118
Triple-negative breast cancer (TNBC) is a highly metastatic and aggressive disease with limited treatment options. Recently, the combination of the immune checkpoint inhibitor (ICI) atezolizumab (anti-PD-L1) with nab-paclitaxel was approved...
5.
Christmas B, Rafie C, Hopkins A, Scott B, Ma H, Cruz K, et al.
Cancer Immunol Res
. 2018 Oct;
6(12):1561-1577.
PMID: 30341213
Immune-checkpoint inhibition (ICI) has revolutionized treatment in cancers that are naturally immunogenic by enabling infiltration of T cells into the tumor microenvironment (TME) and promoting cytotoxic signaling pathways. Tumors possessing...